Detection of the Atherosclerotic PCSK9 gene Inhibitors Through in silico Method to Improve Targeted Therapy
Abstract
Keywords
Full Text:
PDFReferences
Abraham, M. J., Murtola, T., Schulz, R., Páll, S., Smith, J. C., Hess, B., & Lindah, E. (2015). Gromacs: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX, 1–2, 19–25. https://doi.org/10.1016/j.softx.2015.06.001
Andreadou, I., Iliodromitis, E. K., Lazou, A., Görbe, A., Giricz, Z., Schulz, R., & Ferdinandy, P. (2017). Effect of hypercholesterolaemia on myocardial function, ischaemia–reperfusion injury and cardioprotection by preconditioning, postconditioning and remote conditioning. In British Journal of Pharmacology (Vol. 174, Issue 12). https://doi.org/10.1111/bph.13704
Attique, S. A., Hassan, M., Usman, M., Atif, R. M., Mahboob, S., Al-Ghanim, K. A., Bilal, M., & Nawaz, M. Z. (2019). A molecular docking approach to evaluate the pharmacological properties of natural and synthetic treatment candidates for use against hypertension. International Journal of Environmental Research and Public Health, 16(6), 1–17. https://doi.org/10.3390/ijerph16060923
Bass, J. W. (1973). Oral Antipyretic Therapy-Reply. American Journal of Diseases of Children, 126(4), 564. https://doi.org/10.1001/archpedi.1973.02110190459029
Bateman, A., Martin, M. J., O’Donovan, C., Magrane, M., Apweiler, R., Alpi, E., Antunes, R., Arganiska, J., Bely, B., Bingley, M., Bonilla, C., Britto, R., Bursteinas, B., Chavali, G., Cibrian-Uhalte, E., Da Silva, A., De Giorgi, M., Dogan, T., Fazzini, F., … Zhang, J. (2015). UniProt: A hub for protein information. Nucleic Acids Research, 43(D1), D204–D212. https://doi.org/10.1093/nar/gku989
Bawazeer, N. A., Choudhry, H., Zamzami, M. A., Abdulaal, W. H., Middleton, B., & Moselhy, S. S. (2016). Role of hesperetin in LDL-receptor expression in hepatoma HepG2 cells. BMC Complementary and Alternative Medicine, 16(1), 1–7. https://doi.org/10.1186/s12906-016-1165-2
Burley, S. K., Bhikadiya, C., Bi, C., Bittrich, S., Chen, L., Crichlow, G. V., Christie, C. H., Dalenberg, K., Di Costanzo, L., Duarte, J. M., Dutta, S., Feng, Z., Ganesan, S., Goodsell, D. S., Ghosh, S., Green, R. K., Guranovic, V., Guzenko, D., Hudson, B. P., … Zhuravleva, M. (2021). RCSB Protein Data Bank: Powerful new tools for exploring 3D structures of biological macromolecules for basic and applied research and education in fundamental biology, biomedicine, biotechnology, bioengineering and energy sciences. Nucleic Acids Research, 49(1), D437–D451. https://doi.org/10.1093/nar/gkaa1038
Chaudhary, R., Garg, J., Shah, N., & Sumner, A. (2017). PCSK9 inhibitors: A new era of lipid lowering therapy. World Journal of Cardiology, 9(2), 76. https://doi.org/10.4330/wjc.v9.i2.76
Chu, K. A., & Yalkowsky, S. H. (2009). An interesting relationship between drug absorption and melting point. International Journal of Pharmaceutics, 373(1–2), 24–40. https://doi.org/10.1016/j.ijpharm.2009.01.026
Daina, A., Michielin, O., & Zoete, V. (2017). SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports, 7(January), 1–13. https://doi.org/10.1038/srep42717
Ding, Z., Liu, S., Wang, X., Deng, X., Fan, Y., Sun, C., Wang, Y., & Mehta, J. L. (2015). Hemodynamic shear stress via ROS modulates PCSK9 expression in human vascular endothelial and smooth muscle cells and along the mouse aorta. Antioxidants and Redox Signaling, 22(9), 760–771. https://doi.org/10.1089/ars.2014.6054
Du, F., Hui, Y., Zhang, M., Linton, M. F., Fazio, S., & Fan, D. (2011). Novel domain interaction regulates secretion of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein. Journal of Biological Chemistry, 286(50), 43054–43061. https://doi.org/10.1074/jbc.M111.273474
Ferrari, R., Guardigli, G., & Ceconi, C. (2010). Secondary prevention of CAD with ACE inhibitors: A struggle between life and death of the endothelium. Cardiovascular Drugs and Therapy, 24(4), 331–339. https://doi.org/10.1007/s10557-010-6244-x
Guidi, I., Galimberti, D., Lonati, S., Novembrino, C., Bamonti, F., Tiriticco, M., Fenoglio, C., Venturelli, E., Baron, P., Bresolin, N., & Scarpini, E. (2006). Oxidative imbalance in patients with mild cognitive impairment and Alzheimer’s disease. Neurobiology of Aging, 27(2), 262–269. https://doi.org/10.1016/j.neurobiolaging.2005.01.001
Hanwell, M. D., Curtis, D. E., Lonie, D. C., Vandermeerschd, T., Zurek, E., & Hutchison, G. R. (2012). Avogadro: An advanced semantic chemical editor, visualization, and analysis platform. Journal of Cheminformatics, 4(8). https://doi.org/10.1186/1758-2946-4-17
Horton, J. D., Cohen, J. C., & Hobbs, H. H. (2007). Molecular biology of PCSK9: its role in LDL metabolism. Trends in Biochemical Sciences, 32(2), 71–77. https://doi.org/10.1016/j.tibs.2006.12.008
Horton, J. D., Cohen, J. C., & Hobbs, H. H. (2009). PCSK9: A convertase that coordinates LDL catabolism. Journal of Lipid Research, 50(SUPPL.). https://doi.org/10.1194/jlr.R800091-JLR200
Hyock, J. K., Lagace, T. A., McNutt, M. C., Horton, J. D., & Deisenhofer, J. (2008). Molecular basis for LDL receptor recognition by PCSK9. Proceedings of the National Academy of Sciences of the United States of America, 105(6), 1820–1825. https://doi.org/10.1073/pnas.0712064105
Jaghoori, M. M., Bleijlevens, B., & Olabarriaga, S. D. (2016). 1001 Ways to run AutoDock Vina for virtual screening. Journal of Computer-Aided Molecular Design, 30(3), 237–249. https://doi.org/10.1007/s10822-016-9900-9
Joseph, L., & Robinson, J. G. (2015). Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy. Progress in Cardiovascular Diseases, 58(1), 19–31. https://doi.org/10.1016/j.pcad.2015.04.004
K.R., W., K.R., T., J.A., R., M.P., R., N.J., M., J.F., F., J.D., C., T.-A., N., C.D., F., S.A., T., & M.S., C. (2014). PCSK9 is a critical regulator of the innate immune response and septic shock outcome. Science Translational Medicine, 6(258), 258ra143. http://stm.sciencemag.org/content/6/258/258ra143.full.pdf%0Ahttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed12&NEWS=N&AN=2014858109
Kanaze, F. I., Bounartzi, M. I., Georgarakis, M., & Niopas, I. (2007). Pharmacokinetics of the citrus flavanone aglycones hesperetin and naringenin after single oral administration in human subjects. European Journal of Clinical Nutrition, 61(4), 472–477. https://doi.org/10.1038/sj.ejcn.1602543
Khera, A. V., Won, H. H., Peloso, G. M., Lawson, K. S., Bartz, T. M., Deng, X., van Leeuwen, E. M., Natarajan, P., Emdin, C. A., Bick, A. G., Morrison, A. C., Brody, J. A., Gupta, N., Nomura, A., Kessler, T., Duga, S., Bis, J. C., van Duijn, C. M., Cupples, L. A., … Kathiresan, S. (2016). Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. In Journal of the American College of Cardiology (Vol. 67, Issue 22). Elsevier Ltd. https://doi.org/10.1016/j.jacc.2016.03.520
Kim, S., Chen, J., Cheng, T., Gindulyte, A., He, J., He, S., Li, Q., Shoemaker, B. A., Thiessen, P. A., Yu, B., Zaslavsky, L., Zhang, J., & Bolton, E. E. (2021). PubChem in 2021: New data content and improved web interfaces. Nucleic Acids Research, 49(D1), D1388–D1395. https://doi.org/10.1093/nar/gkaa971
Koes, D. R., & Camacho, C. J. (2012). ZINCPharmer: Pharmacophore search of the ZINC database. Nucleic Acids Research, 40(W1), 409–414. https://doi.org/10.1093/nar/gks378
Langer, T., & Hoffmann, R. D. (2008). Pharmacophore Modelling. Encyclopedia of Molecular Pharmacology, 960–960. https://doi.org/10.1007/978-3-540-38918-7_6434
Laskowski, R. A., Jabłońska, J., Pravda, L., Vařeková, R. S., & Thornton, J. M. (2018). PDBsum: Structural summaries of PDB entries. Protein Science, 27(1), 129–134. https://doi.org/10.1002/pro.3289
Latimer, J., Batty, J. A., Neely, R. D. G., & Kunadian, V. (2016). PCSK9 inhibitors in the prevention of cardiovascular disease. Journal of Thrombosis and Thrombolysis, 42(3), 405–419. https://doi.org/10.1007/s11239-016-1364-1
Leinonen, R., Garcia Diez, F., Binns, D., Fleischmann, W., Lopez, R., & Apweiler, R. (2004). UniProt archive. Bioinformatics, 20(17), 3236–3237. https://doi.org/10.1093/bioinformatics/bth191
Liu, L., & Chen, J. (2008). Solubility of hesperetin in various solvents from (288.2 to 323.2) K. Journal of Chemical and Engineering Data, 53(7), 1649–1650. https://doi.org/10.1021/je800078j
Lonn, E. (2001). Antiatherosclerotic effects of ace inhibitors:Where are we now? American Journal of Cardiovascular Drugs, 1(5), 315–320. https://doi.org/10.2165/00129784-200101050-00001
Lovering, F., Bikker, J., & Humblet, C. (2009). Escape from flatland: Increasing saturation as an approach to improving clinical success. Journal of Medicinal Chemistry, 52(21), 6752–6756. https://doi.org/10.1021/jm901241e
Mahley, R. W. (2016). Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders. Journal of Molecular Medicine, 94(7), 739–746. https://doi.org/10.1007/s00109-016-1427-y
Maxwell, K. N., Soccio, R. E., Duncan, E. M., Sehayek, E., & Breslow, J. L. (2003). Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice. Journal of Lipid Research, 44(11), 2109–2119. https://doi.org/10.1194/jlr.M300203-JLR200
McNutt, M. C., Lagace, T. A., & Horton, J. D. (2007). Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells. Journal of Biological Chemistry, 282(29), 20799–20803. https://doi.org/10.1074/jbc.C700095200
Petrilli, W. L., Adam, G. C., Erdmann, R. S., Abeywickrema, P., Agnani, V., Ai, X., Baysarowich, J., Byrne, N., Caldwell, J. P., Chang, W., DiNunzio, E., Feng, Z., Ford, R., Ha, S., Huang, Y., Hubbard, B., Johnston, J. M., Kavana, M., Lisnock, J. M., … Imbriglio, J. E. (2020). From Screening to Targeted Degradation: Strategies for the Discovery and Optimization of Small Molecule Ligands for PCSK9. Cell Chemical Biology, 27(1), 32-40.e3. https://doi.org/10.1016/j.chembiol.2019.10.002
Pines, A., & Fisman, E. Z. (2003). ACE inhibition with moexipril: A review of potential effects beyond blood pressure control. American Journal of Cardiovascular Drugs, 3(5), 351–360. https://doi.org/10.2165/00129784-200303050-00006
Pitt, B. (1995). Potential role of angiotensin converting enzyme inhibitors in the treatment of atherosclerosis. European Heart Journal, 16(SUPPL. K), 49–54. https://doi.org/10.1093/eurheartj/16.suppl_k.49
RA, L., & MB, S. (2011). LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. Journal of Chemical Information and Modeling, 51, 2778–2786.
Ramharack, P., & Soliman, M. E. S. (2018). Bioinformatics-based tools in drug discovery: the cartography from single gene to integrative biological networks. Drug Discovery Today, 23(9), 1658–1665. https://doi.org/10.1016/j.drudis.2018.05.041
Schneidman-Duhovny, D., Dror, O., Inbar, Y., Nussinov, R., & Wolfson, H. J. (2008). Deterministic pharmacophore detection via multiple flexible alignment of drug-like molecules. Journal of Computational Biology, 15(7), 737–754. https://doi.org/10.1089/cmb.2007.0130
Seidah, N. G., Abifadel, M., Prost, S., Boileau, C., & Prat, A. (2017). The proprotein convertases in hypercholesterolemia and cardiovascular diseases: Emphasis on proprotein convertase subtilisin/Kexin 9. Pharmacological Reviews, 69(1), 33–52. https://doi.org/10.1124/pr.116.012989
Semenova, A. E., Sergienko, I. V., GarcÃa-Giustiniani, D., Monserrat, L., Popova, A. B., Nozadze, D. N., & Ezhov, M. V. (2020). Verification of underlying genetic cause in a cohort of russian patients with familial hypercholesterolemia using targeted next generation sequencing. Journal of Cardiovascular Development and Disease, 7(2). https://doi.org/10.3390/JCDD7020016
Shelness, G. S., & Sellers, J. A. (2001). Very-low-density lipoprotein assembly and secretion. Current Opinion in Lipidology, 12(2), 151–157. https://doi.org/10.1097/00041433-200104000-00008
Sterling, T., & Irwin, J. J. (2015). ZINC 15 - Ligand Discovery for Everyone. Journal of Chemical Information and Modeling, 55(11), 2324–2337. https://doi.org/10.1021/acs.jcim.5b00559
Ukuku, D. O., Bari, L., & Kawamoto, S. (2012). Hydrogen Peroxide. Decontamination of Fresh and Minimally Processed Produce, 2, 197–214. https://doi.org/10.1002/9781118229187.ch11
Urban, D., Pöss, J., Böhm, M., & Laufs, U. (2013). Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. Journal of the American College of Cardiology, 62(16), 1401–1408. https://doi.org/10.1016/j.jacc.2013.07.056
Wan, Q., Liu, Z., Yang, Y., & Cui, X. (2018). Suppressive effects of berberine on atherosclerosis via downregulating visfatin expression and attenuating visfatin-induced endothelial dysfunction. International Journal of Molecular Medicine, 41(4), 1939–1948. https://doi.org/10.3892/ijmm.2018.3440
Waterhouse, A., Bertoni, M., Bienert, S., Studer, G., Tauriello, G., Gumienny, R., Heer, F. T., De Beer, T. A. P., Rempfer, C., Bordoli, L., Lepore, R., & Schwede, T. (2018). SWISS-MODEL: Homology modelling of protein structures and complexes. Nucleic Acids Research, 46(W1), W296–W303. https://doi.org/10.1093/nar/gky427
Wei, W., Cherukupalli, S., Jing, L., Liu, X., & Zhan, P. (2020). Fsp3: A new parameter for drug-likeness. Drug Discovery Today, 25(10), 1839–1845. https://doi.org/10.1016/j.drudis.2020.07.017
Wishart, D. S. (2005). Bioinformatics in drug development and assessment. In Drug Metabolism Reviews (Vol. 37, Issue 2). https://doi.org/10.1081/DMR-200055225
Xu, S., Luo, S., Zhu, Z., & Xu, J. (2019). Small molecules as inhibitors of PCSK9: Current status and future challenges. European Journal of Medicinal Chemistry, 162, 212–233. https://doi.org/10.1016/j.ejmech.2018.11.011
Yamada, Y., Gohda, S., Abe, K., Togo, T., Shimano, N., Sasaki, T., Tanaka, H., Ono, H., Ohba, T., Kubo, S., Ohkubo, T., & Sato, S. (2017). Carbon materials with controlled edge structures. Carbon, 122(October 1995), 694–701. https://doi.org/10.1016/j.carbon.2017.07.012
Yang, H., Lou, C., Sun, L., Li, J., Cai, Y., Wang, Z., Li, W., Liu, G., & Tang, Y. (2019). AdmetSAR 2.0: Web-service for prediction and optimization of chemical ADMET properties. Bioinformatics, 35(6), 1067–1069. https://doi.org/10.1093/bioinformatics/bty707
Younas, F., Aslam, B., Muhammad, F., Mohsin, M., Raza, A., Faisal, M. N., Shamshud-Ul-Hassan, & Majeed, W. (2017). Haematopoietic effects of angelica sinensis root cap polysaccharides against lisinopril-induced anaemia in albino rats. Pharmaceutical Biology, 55(1), 108–113. https://doi.org/10.1080/13880209.2016.1230635
Zhang, D., Wang, Y., Yi, M., Zhang, S., & Wu, Y. (2020). The Peroxisome Proliferator-Activated Receptor γ Agonist Pioglitazone Protects Vascular Endothelial Function in Hypercholesterolemic Rats by Inhibiting Myeloperoxidase. Cardiology Research and Practice, 2020. https://doi.org/10.1155/2020/1845969
Zhao, P. J., Ban, M. R., Iacocca, M. A., McIntyre, A. D., Wang, J., & Hegele, R. A. (2019). Genetic Determinants of Myocardial Infarction Risk in Familial Hypercholesterolemia. CJC Open, 1(5), 225–230. https://doi.org/10.1016/j.cjco.2019.06.001
DOI: https://doi.org/10.14421/biomedich.2022.112.119-131
Refbacks
- There are currently no refbacks.
Copyright (c) 2022 Sabarinathan Sethuramalingam, Revathy Leena Ravi, Janet Rani Rajiah
Biology, Medicine, & Natural Product Chemistry |